• Login
    View Item 
    •   NM-AIST Home
    • Life sciences and Bio-engineering
    • PhD Theses and Dissertations [LiSBE]
    • View Item
    •   NM-AIST Home
    • Life sciences and Bio-engineering
    • PhD Theses and Dissertations [LiSBE]
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Application of molecular methods in optimizing clinical management of patients with pulmonary multidrug resistant tuberculosis in Tanzania

    Thumbnail
    View/Open
    Full text (4.283Mb)
    Date
    2021-12
    Author
    Mbelele, Peter
    Metadata
    Show full item record
    Abstract
    Rifampicin or multidrug-resistant tuberculosis (RR/MDR-TB) accounts for considerable morbidity and mortality. Differences among Mycobacterium tuberculosis complex (MTBC) species may predict drug-resistance or treatment success. This thesis aimed at identifying MTBC at species level, their drug-resistance patterns, and mycobactericidal effect of different regimens in patients treated for RR/MDR-TB and drug-susceptible (DS-TB). This was a cross sectional study nested in a longitudinal design that followed patients on RR/MDR-TB and DS TB treatment for 4 months. While RR/MDR-TB patients received bedaquiline with or without an injectable-aminoglycoside based regimen, DS-TB patients received a fixed-dose combination comprised of rifampicin-isoniazid-pyrazinamid-ethambutol (RHZE). The genotype MTBC assay was used to identify MTBC species. WGS-based drug resistant mutations predicted the minimum-inhibitory-concentration (MIC) of antibiotics measured in the MycoTB-Sensitire™ assay. An isolate was categorised as resistant and susceptible if it had a MIC above and at or below the epidemiological-cut-off (ECOFF) value, respectively. Non linear-mixed effects modelled the MTBC killing rates measured by Tuberculosis molecular bacterial load assay and culture. The median MIC at their 25th and 75th interquartile range (IQR) were compared using Mann-Whitney U test. Among 126 patients, 89 (71%) had positive culture whereas 87 (98%) were identified as M. tuberculosis. Overall, mutant (gNWT-R) MTBC isolates correlated with MIC values above the ECOFF. For instance, the median MIC (µg/mL) for rifampicin-gNWT-R strains was > 4.0 (IQR; 4.0 – 4.0) compared to 0.5 (IQR; 0.38 – 0.50) in non-mutant (gWT-S, p < 0.001); isoniazid-gNWT-R > 4.0 (IQR; 2.0 – 4.0) compared to 0.25 (IQR; 0.12 – 1.00) among gWT-S (p = 0.001); ethionamide-gNWT-R 15.0 (IQR; 10.0 – 20.0) compared to 2.50 (IQR; 2.50 – 5.00) among gWT-S (p < 0.001). There were no detectable mutations in genes previously known to confer fluoroquinolones, aminoglycosides, capreomycin, bedaquiline, delamanid, linezolid, clofazimine, cycloserine, and p aminosalicylic acid resistance. Compared to the adjusted M. tuberculosis killing rate of -0.17 (95% CI; -0.23 to -0.12) for the injectable without bedaquiline reference regimen, the killing rates were -0.62 (95% CI; -1.05 to -0.20) log10 eCFU/mL for the injectable with bedaquiline containing regimen (p = 0.019), -0.35 (95% CI; -0.65 to -0.13) log10 eCFU/mL for the all-oral bedaquiline-based regimen (p = 0.054), and -0.29 (95% CI; -0.78 to +0.22) log10 eCFU/mL for RHZE (p = 0.332). The detected M. tuberculosis was susceptible to core drugs including bedaquiline, fluoroquinolones, linezolid, and clofazimine, supporting their central use in the RR/MDRTB treatment regimens. M. tuberculosis killing rates were higher among patients who received bedaquiline but were further improved with addition of an injectable aminoglycoside.
    URI
    https://doi.org/10.58694/20.500.12479/1547
    Collections
    • PhD Theses and Dissertations [LiSBE]

    Nelson Mandela-AIST copyright © 2021  DuraSpace
    Theme by 
    Atmire NV
     

     

    Browse

    All PublicationsCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Nelson Mandela-AIST copyright © 2021  DuraSpace
    Theme by 
    Atmire NV